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AnalysisGenomics in Africa:
Avoiding Past PitfallsA landmark genomics project is taking shape in Africa that shifts
the power and prominence to local scientists. If successful, the
program will offer valuable insights into the inheritance of
common diseases and reshape the paradigm of foreign-funded
research.In the past few years, large-scale geno-
mics studies have made one point
clear: scientistsmust screen the genomes
of diverse populations around the world
to decipher the genetic basis of common
diseases. But the relationship between
genomicists and indigenous populations
is often contentious. Although biomedical
projects are more positively received
than evolutionary studies, the prevailing
structure still bears elements of neocolo-
nialism; European and American scien-
tists gather samples and return home to
analyze and publish the results. This
imbalance breeds skepticism for projects
and limits participation.
Starting this October, the US’s NIH
and the UK’s Wellcome Trust are joining
forces to restructure this paradigm by
developing a genomics research net-
work across Africa. Named The Human
Heredity and Health in Africa Project, or
H3Africa, the program plans to give
African researchers an opportunity to bid
for research grants to study diverse topics
in genomics, from the human microbiome
and pharmogenomics to the genetics of
communicable and noncommunicable
diseases.
Those selected for funding will establish
or enhance local research facilities in their
home country to generate modern se-
quencing and phenotyping laboratories.
These centers will also serve as training
facilities and function within a network of
clinics and bioinformatics laboratories.
The hope is that the genetic work will prove
useful in combating diseases that are
specifically problematic in Africa but will
also yield insight into the genes behind
global diseases, like diabetes and cancer.
The project naturally elicits the question
of ‘‘why Africa.’’ Indeed, it would be lessexpensive and politically far simpler to
have western researchers continue to
sample western genes, but that would
yield an incomplete picture of human
genetic variation. The reason is that Africa
is a genetically special place.
Why Africa
In May 2009, a study published in Science
sent shockwaves through the field of
human genetics when it reported the
most comprehensive analysis of African
genetic diversity to date (Tishkoff et al.,
2009, Science 324, 1035–1044). Led
by Sarah Tishkoff at the University of
Pennsylvania, the study looked at
1327 nuclear microsatellite and insertion/
deletion markers in 2,400 individuals—
a diminutive scale and scope compared
to sequencing and genome-wide associ-
ation studies reported today. But what
made Tishkoff’s study so extraordinary
were the individuals themselves.
Most genetic studies in African had
sampled only a handful of groups and
then generalized their findings. In con-
trast, Tishkoff and her team acquired
samples from 113 distinct populations
across the continent, from the Mozabite
Berbers of Morocco to the hunter-gath-
erer San of the Kalahari Desert. The find-
ings made it clear that Africa was home
to the highest levels of human genetic
diversity on the planet.
The reason for this vast diversity is that
migration has reduced genetic variation
in populations outside of Africa. Just as
people today move to take advantage of
low housing prices or new jobs, ancient
humans moved to find new forms of
shelter and food. A major threat faced by
these migratory populations was genetic
isolation; inbreeding decreased geneticCell 147, Sdiversity and increased the population’s
vulnerability to disease.
Today, human populations decrease in
genetic diversity the further away they get
from Africa because founder populations
that were formed from other founder pop-
ulations shrunk the gene pool further. For
instance, a study last year reported the
complete genome (or exome) sequences
of four individuals from a hunter-gatherer
population in Southern Africa called
Khosians. Despite their geographic prox-
imity, the Khosians were genetically quite
far apart, with more differences in their
genes than those observed between
Europeans and Asians (Schuster et al.,
2010, Nature 463, 943–947).
Researchers keen to find genes that
contribute to diseases are limiting the
variations that they have available for
study if they restrict their search to indi-
viduals outside of Africa.
To date, however, genomic studies
have focused almost exclusively on west-
erners.Approximately96%of thesubjects
in genome-wide association studies so far
are fromEuropean descent. Findings from
these studies may not generalize to other
populations, and they may also miss
many alleles that are rare in Europeans
but more frequent in other ethnic groups.
‘‘A lot of past work has been Eurocen-
tric, and that is not good. We need to
know much more about the genetics of
humans worldwide, particularly Africa,’’
says geneticist Nick Patterson at the
Broad Institute.
Genetically, in comparison to most
other human populations, Africans have
more haplotypes (combinations of alleles
in different loci) and lower levels of linkage
disequilibrium (alleles on the same chro-
mosome are more likely to be inherited
independently of each other). ‘‘These
allow for fine-mapping and better locali-
zation of risk variants in genomic loci,’’
says Charles Rotimi, president of the
African Society of Human Genetics and
director of the Center for Research on
Genomics and Global Health at the NIH.
But the reasons for going to Africa are
not solely genetic ones. ‘‘In the devel-
oping countries that I’ve visited, there
is a large community with tremendous
intellectual capacity. We really want to
reverse the history of not involving African
communities and see to it that the people
of Africa reap the health benefits that willeptember 30, 2011 ª2011 Elsevier Inc. 11
Phenetic tree of human populations around the world. African branches are color coded according to language classifications. The two
insets show principal components analysis created on the basis of individual genotype. Adapted from Tishkoff et al., 2009, Science 324,
1035–1044.result from analysis of their genetics,’’
says Jane Peterson, associate director
of extramural research at the NIH.
‘‘Over the years, it has been very frus-
trating working in genomics and seeing
so few Africans participate. Creating
a research environment where young
African men and women can pursue this
research on their own is everything,’’
says Dr Rotimi.
Yet the path forward is not without
obstacles.
Colonial Ghosts
Whether justified or not, a connection
could be made between historic colonial
mining of African resources and the
western funding of projects that will
mine African genomes. Indeed, Africans
need not look to colonial times to have12 Cell 147, September 30, 2011 ª2011 Elseconcerns about misuse of collected bio-
logical resources.
In 1983, blood samples were collected
from natives of the Nuu-chah-nulth tribe
on Vancouver Island by researchers.
Rheumatoid arthritis was a serious
problem among the indigenous popula-
tion. The tribe had agreed with the scien-
tists using their blood to search for genes
associated with rheumatoid arthritis, with
the hopes of alleviating pain in their
community.
The researchers were unable to find any
genetic basis for the arthritis during the
1980s, and when the lead researcher
behind this work moved to a new univer-
sity in 1986, so did the Nuu-chah-nulth
blood samples. Over time, the samples
were shared with other researchers, and
studies were conducted on them that didvier Inc.not involve rheumatoid arthritis at all.
When the tribe ultimately discovered that
studies, including one on viruses spread
by intravenous drug use, were being con-
ducted on their biological sampleswithout
their permission, tensions rose and an
international debate emerged over the
proper care of genetic samples.
‘‘This was all about expectations not
being met and the people not being
involved in the decisions to carry out
secondary research after the initial re-
search could not be completed,’’ explains
Laura Arbour at the University of
British Columbia, a medical geneticist
who was not involved with the Nuu-chah-
nulth work. ‘‘People who live with health
disparity want research money spent in
ways that can make a difference for
them. But research is a dynamic process.
Thingschange.Resultsmayunexpectedly
lead to a different path or the research in-
tended cannot be completed. If new
research is being proposed for their
samples, they should be included in that
discussion too,’’ she says.
Making African Research African
To avoid creating a Nuu-chah-nulth
debacle and to promote independence
from NIH support, keeping research
inside of Africa is a priority for the new
project.
During the next five years, considerable
funding—five million dollars a year from
the NIH and eight million pounds a year
from the Wellcome Trust—is going to be
awarded in the form of grants to African
researchers by an NIH-selected peer
review team. However, collaboration
with labs outside of Africa is undoubtedly
going to happen, and this means that
some African samples may need to leave
the continent.
Keenly aware that even sending some
blood and DNA out of Africa might
generate the wrong message, H3Africa
is leaving control of biological materials
collected in Africa to researchers from
the continent. ‘‘African researchers will
develop the policy for sample distribu-
tion,’’ says Peterson. Yet because the
project is still in its infancy, the fundersbehind H3Africa will not guarantee that
an African biorepository for material
storage and management will be built.
‘‘A biorepository remaining on African
soil and under the governance of African
researchers and other local stake-
holders is an ideal way to reduce the risk
of unapproved secondary research,’’
comments Dr Arbour. ‘‘But if the samples
need to be analyzed elsewhere, it remains
possible that the protective processes
can still be effective as long as all parties
are on board and the governance remains
with the African partners,’’ she says.
It also remains to be determined what
diseases will get studied and to what
extent they will include diseases that are
specifically problematic in Africa, as the
project’s future revolves around the
research proposals that come in during
the months ahead. The funding bodies
behind H3Africa are not formally declaring
any diseases that they are keen to see
fought. ‘‘I would guess that we will see
a mix chosen since one of the key criteria
that will be used by the peer reviewers is
medical relevance, and there are certainly
a lot of highly relevant diseases shared
by both Africa and the rest of the world,’’
says Peterson. But this silence from the
funding agency is not stopping individuals
from expressing what they would like to
see studied.Cell 147, S‘‘A distressingly high proportion of
young children in Africa pick up lethal diar-
rhea. I suspect that this has been persist-
ing in Africa for a long time. Since it sets
in before reproductive age and selection
probably has been playing a role in select-
ing for infants that can survive the disease,
there might be some genetic resistance
there, and this may be well worth looking
for,’’ says Patterson.
As for Rotimi, he is keen to see sickle
cell anemia dealt with. ‘‘In some areas of
western Africa, heterozygotes can be as
common as 20% of the population, while
actual sickle cell patients (sufferers) can
be up to 3%. Many sufferers never make
it to medical facilities alive. In addition, it
is often assumed that carriers are entirely
normal, but we really do not know that!
Research directed at understanding this
disease, its complications, and treatment
has not received enough scientific atten-
tion, and this needs to change,’’ says
Rotimi.
Indeed, the project looks well aimed
to avoid past pitfalls, and with the right
project proposals, it could have a pro-
found impact on our understanding of
disease inheritance and human evolution.
But there is still a long way to go to narrow
the gap between Africans’ genetic rich-
ness and their power to use it for their
own benefit.Matt Kaplan
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